 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12...7891011121314151617...2728» |
- | goserelin acetate / Generic mfg.
Trial completion date, Trial primary completion date: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females (clinicaltrials.gov) - Jan 22, 2021
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | goserelin acetate / Generic mfg.
Trial completion: Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity (clinicaltrials.gov) - Jan 13, 2021
P3, N=330, Completed, Sponsor: Xiangyun Zong
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Active, not recruiting --> Completed
- | goserelin acetate / Generic mfg.
Trial completion, Trial completion date: BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH (clinicaltrials.gov) - Jan 12, 2021
P=N/A, N=41, Completed, Sponsor: 424 General Military Hospital
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Mar 2021 --> Dec 2020
- | Xofigo (radium Ra-223 dichloride) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 7, 2021
P2, N=24, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed | Trial completion date: Mar 2021 --> Dec 2020 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||| amcenestrant (SAR439859) / Sanofi
Trial primary completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Jan 4, 2021
P3, N=810, Recruiting, Sponsor: Sanofi
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial primary completion date: Jan 2024 --> May 2024
- | Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Trial completion date, Trial primary completion date: ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Dec 30, 2020
P2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Jan 2024 --> May 2024 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Erleada (apalutamide) / J&J
Enrollment closed, Combination therapy, Metastases: YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov) - Dec 29, 2020
P2, N=31, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting
- || Erleada (apalutamide) / J&J
Enrollment closed, Trial completion date, Metastases: LACOG 0415: Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels (clinicaltrials.gov) - Dec 29, 2020
P2, N=128, Active, not recruiting, Sponsor: Latin American Cooperative Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Apr 2021
- ||| goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. (clinicaltrials.gov) - Dec 19, 2020
P4, N=871, Not yet recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Apr 2021 N=104 --> 871 | Trial completion date: Jan 2022 --> Oct 2022 | Trial primary completion date: Jan 2022 --> Oct 2022
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer (clinicaltrials.gov) - Dec 17, 2020
P3, N=200, Recruiting, Sponsor: Kyoto Breast Cancer Research Network
N=104 --> 871 | Trial completion date: Jan 2022 --> Oct 2022 | Trial primary completion date: Jan 2022 --> Oct 2022 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Mar 2021
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: PALOMA3: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) (clinicaltrials.gov) - Dec 16, 2020
P3, N=521, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Mar 2021 Trial completion date: Dec 2020 --> May 2021
- ||| goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Trial completion date: PCS III: Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone (clinicaltrials.gov) - Dec 9, 2020
P3, N=600, Active, not recruiting, Sponsor: Abdenour Nabid
Trial completion date: Dec 2020 --> May 2021 Trial completion date: Dec 2020 --> Dec 2025
- | Kisqali (ribociclib) / Novartis
Biomarker, New trial: LEANORA: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (clinicaltrials.gov) - Dec 7, 2020
P, N=36, Not yet recruiting, Sponsor: Georgetown University
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
Zoladex lo puedes conseguir en BADAN (Twitter) - Dec 2, 2020
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial primary completion date, Metastases: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (clinicaltrials.gov) - Nov 30, 2020
P3, N=608, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2020 --> Dec 2025 Trial primary completion date: Jan 2021 --> May 2020
- |||||| Erleada (apalutamide) / J&J
Enrollment open: PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov) - Nov 22, 2020
P3, N=412, Recruiting, Sponsor: Janssen-Cilag Ltd.
Trial primary completion date: Jan 2021 --> May 2020 Not yet recruiting --> Recruiting
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
Journal: Development and validation of an LC-MS/MS method for the quantification of goserelin in a Pheroid® formulation, in simulated intestinal fluid. (Pubmed Central) - Nov 19, 2020
A simple, reproducible and good recovery extraction procedure for goserelin quantification was achieved through simultaneous acetonitrile protein precipitation and water-saturated n-butanol liquid-liquid extraction with water dilution. The method was found to be rapid, specific, precise and accurate, and successfully applied to determine goserelin remaining content in a simulated intestinal fluid, with potential use in other lipid-based formulation evaluated in simulated intestinal fluids.
- || giredestrant (GDC-9545) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - Nov 17, 2020
P1a/1b, N=220, Recruiting, Sponsor: Genentech, Inc.
The method was found to be rapid, specific, precise and accurate, and successfully applied to determine goserelin remaining content in a simulated intestinal fluid, with potential use in other lipid-based formulation evaluated in simulated intestinal fluids. Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Nov 13, 2020
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022 Trial primary completion date: Sep 2020 --> May 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Rubraca (rucaparib) / Pharma& Schweiz
Trial initiation date, Metastases: CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov) - Nov 12, 2020
P3, N=1002, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2020 --> May 2021 Initiation date: Sep 2020 --> Jan 2021
- || Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
Clinical, Journal: Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report. (Pubmed Central) - Nov 11, 2020
We hope to provide an attractive evidence for neoadjuvant endocrine therapy of neuroendocrine carcinoma of the breast. However, more cases are still being needed for research.
- || tamoxifen / Generic mfg.
Clinical, Journal: Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. (Pubmed Central) - Nov 6, 2020
P3
However, more cases are still being needed for research. Better clinical responses were observed in pre-menopausal patients after 24 weeks of NCT compared to those observed after NET.
- | goserelin acetate / Generic mfg.
Trial completion, Trial completion date, Combination therapy: AADLPC: Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer (clinicaltrials.gov) - Nov 3, 2020
P3, N=362, Completed, Sponsor: Fundaci
Better clinical responses were observed in pre-menopausal patients after 24 weeks of NCT compared to those observed after NET. Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2020
- | goserelin acetate / Generic mfg.
Enrollment closed: Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (clinicaltrials.gov) - Oct 28, 2020
P2, N=80, Active, not recruiting, Sponsor: University of British Columbia
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2020 Recruiting --> Active, not recruiting
- |||||| amcenestrant (SAR439859) / Sanofi
Enrollment open, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 25, 2020
P3, N=810, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: PALTAN: Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (clinicaltrials.gov) - Oct 13, 2020
P2, N=26, Terminated, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=48 --> 26 | Trial completion date: Dec 2021 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Aug 2020; Futility
- | Erleada (apalutamide) / J&J
Enrollment open, Surgery: INDICATE: Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (clinicaltrials.gov) - Oct 11, 2020
P3, N=804, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
N=48 --> 26 | Trial completion date: Dec 2021 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Aug 2020; Futility Not yet recruiting --> Recruiting
- |||| amcenestrant (SAR439859) / Sanofi
Trial primary completion date, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 7, 2020
P3, N=810, Not yet recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2026 --> Jan 2024
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Oct 6, 2020
P2, N=92, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Sep 2026 --> Jan 2024 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- | Turalio (pexidartinib) / Daiichi Sankyo
Biomarker, Trial completion, Enrollment change, Tumor microenvironment: PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer (clinicaltrials.gov) - Oct 6, 2020
P1, N=8, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Suspended --> Completed | N=24 --> 8
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap, bicalutamide / Generic mfg.
Journal: Ulcerative colitis that developed during radiotherapy for prostate cancer, deteriorated rapidly and required emergency surgery. (Pubmed Central) - Oct 3, 2020
Suspended --> Completed | N=24 --> 8 When a patient exhibits diarrhea while undergoing radiotherapy for PC, clinicians should be aware of the possibility of UC in addition to radiation colitis, and colonoscopy should be considered.
- | Kisqali (ribociclib) / Novartis
Trial completion date, Metastases: TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer (clinicaltrials.gov) - Sep 30, 2020
P1, N=7, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
When a patient exhibits diarrhea while undergoing radiotherapy for PC, clinicians should be aware of the possibility of UC in addition to radiation colitis, and colonoscopy should be considered. Trial completion date: Aug 2020 --> Dec 2020
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open: CARABELA: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (clinicaltrials.gov) - Sep 29, 2020
P2, N=200, Recruiting, Sponsor: Spanish Breast Cancer Research Group
Trial completion date: Aug 2020 --> Dec 2020 Not yet recruiting --> Recruiting
- |||||| Erleada (apalutamide) / J&J
Enrollment open: CARLHA-2: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (clinicaltrials.gov) - Sep 23, 2020
P3, N=490, Recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting Suspended --> Recruiting
- |||||||||| Erleada (apalutamide) / J&J
New P3 trial: PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov) - Sep 19, 2020
P3, N=412, Not yet recruiting, Sponsor: Janssen-Cilag Ltd.
- Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
[VIRTUAL] Gender-affirming Hormones Are Associated With Increased Risk of QT Prolongation in Transgender Females (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_1135;
This needs to be interpreted with caution owing to the very small sample size in this study. Further studies to investigate the strength of this association, if it exists, are warranted.
- || Rozlytrek (entrectinib) / Roche
New P2 trial, Combination therapy: Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (clinicaltrials.gov) - Sep 15, 2020
P2, N=45, Not yet recruiting, Sponsor: Jules Bordet Institute
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Enrollment change: Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Sep 9, 2020
P2, N=24, Active, not recruiting, Sponsor: NSABP Foundation Inc
Further studies to investigate the strength of this association, if it exists, are warranted. Recruiting --> Active, not recruiting | N=76 --> 24
- ||| tamoxifen / Generic mfg.
Clinical, P3 data, Journal: Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. (Pubmed Central) - Sep 9, 2020
Recruiting --> Active, not recruiting | N=76 --> 24 The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy.
- | goserelin acetate / Generic mfg.
New P2 trial: Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients (clinicaltrials.gov) - Sep 2, 2020
P2, N=34, Completed, Sponsor: Beni-Suef University
- || Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
We can medically induce menopause with a medicine like zoladex and see if that makes it better...but I have to say that is rarely my experience. (Twitter) - Sep 1, 2020
- |||| Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
Clinical: "Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy" (2015) administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility. https://t.co/gqjSE6cjct (Twitter) - Aug 29, 2020
- | Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Combination therapy, Metastases: YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov) - Aug 20, 2020
P2, N=24, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy. Trial completion date: Sep 2022 --> Jul 2021 | Trial primary completion date: Nov 2021 --> Mar 2021
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap, Suprefact (buserelin acetate) / Sanofi
Journal: Comparison of clinical efficacy of long- versus short-acting gonadotrophin-releasing hormone agonists for pituitary down regulation in In vitro fertilisation cycles. (Pubmed Central) - Aug 20, 2020
While group B had a significantly higher number of hospital visits (P = 0.0001) as well as a higher number of injections (P = 0.0001), the mean cost of GnRHa and gonadotrophin used was significantly higher in Group A (P = 0.043). Single-dose long-acting GnRHa is as effective as daily dose short-acting GnRHa for pituitary desensitisation prior to controlled ovarian stimulation in IVF cycles.
- | Suprefact (buserelin acetate) / Sanofi, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
New P3 trial: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Aug 13, 2020
P3, N=2478, Not yet recruiting, Sponsor: NRG Oncology
- | Visanne (dienogest) / Mochida, Bayer
Enrollment change, Trial termination, Head-to-Head: Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin (clinicaltrials.gov) - Aug 13, 2020
P4, N=14, Terminated, Sponsor: University of Sao Paulo
Single-dose long-acting GnRHa is as effective as daily dose short-acting GnRHa for pituitary desensitisation prior to controlled ovarian stimulation in IVF cycles. N=63 --> 14 | Not yet recruiting --> Terminated; PI went for a post-doc course and when he came back he moved for another job
- | goserelin acetate / Generic mfg., anastrozole / Generic mfg.
Phase classification, Enrollment change, Trial termination: Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy (clinicaltrials.gov) - Aug 13, 2020
P=N/A, N=5, Terminated, Sponsor: University of Sao Paulo
N=63 --> 14 | Not yet recruiting --> Terminated; PI went for a post-doc course and when he came back he moved for another job Phase classification: P3 --> P=N/A | N=50 --> 5 | Recruiting --> Terminated; No grant was received then we stopped the recruitment
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Trial primary completion date, Metastases: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 11, 2020
P2, N=28, Active, not recruiting, Sponsor: City of Hope Medical Center
Phase classification: P3 --> P=N/A | N=50 --> 5 | Recruiting --> Terminated; No grant was received then we stopped the recruitment Trial completion date: Mar 2020 --> Aug 2021 | Trial primary completion date: Mar 2020 --> Aug 2021
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, HEOR, Combination therapy: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Aug 11, 2020
P2, N=257, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Mar 2020 --> Aug 2021 | Trial primary completion date: Mar 2020 --> Aug 2021 Trial primary completion date: Mar 2020 --> Jul 2020
- | Erleada (apalutamide) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (clinicaltrials.gov) - Aug 8, 2020
P2, N=42, Active, not recruiting, Sponsor: Tian Zhang, MD
Trial primary completion date: Mar 2020 --> Jul 2020 Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Feb 2023 | Trial primary completion date: Mar 2024 --> Feb 2023